

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CARsgen Therapeutics Holdings Limited

科濟藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2171)

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND NON-COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of CARsgen Therapeutics Holdings Limited (the “**Company**”) announces that Mr. Huaqing GUO (“**Mr. Guo**”) tendered his resignation as a non-executive Director with effect from September 30, 2026 due to his other business commitments which require more of his attention and dedication.

Following the resignation of Mr. Guo, he also ceased to act as a member of the audit committee of the Board (the “**Audit Committee**”).

Mr. Guo confirmed that he has no claim against the Company and has no disagreement with the Board and there are no other matters with respect to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

In connection with the resignation of Mr. Guo as a Director, the Company sincerely thanks him for the valuable time and dedication devoted throughout his many years of tenure alongside the Company’s growth and development. The Company extends sincere appreciation for his significant contributions to the Company’s operations and strategic development, and wish him every success in all future endeavours.

NON-COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES

Following the resignation of Mr. Guo, the Audit Committee has two members, Ms. Xiangke ZHAO, an independent non-executive Director, as the chairperson, and Dr. Wen ZHOU, an independent non-executive Director, as a member. Therefore, the composition of the Audit Committee does not meet the minimum number of members in the audit committee as required under Rule 3.21 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Board will make its best endeavours to identify a suitable candidate to fill the vacancy as soon as practicable, with the relevant appointment to be made within three months from the date of resignation to ensure the compliance with the Listing Rules. Further announcement will be made by the Company as and when appropriate.

By order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, September 30, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Ronggang XIE as non-executive Director; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as the independent non-executive Directors.

In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.